Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.

[1]  H. Uemura,et al.  Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma , 2013, British Journal of Cancer.

[2]  T. Rižner,et al.  Correlation between erythropoietin receptor(s) and estrogen and progesterone receptor expression in different breast cancer cell lines. , 2013, International journal of molecular medicine.

[3]  Ting-ting Yu,et al.  [Expression of erythropoietin and erythropoietin receptor in non-small cell lung cancer and its correlation with microvessel density]. , 2012, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[4]  F. Fang,et al.  Clinical significance of erythropoietin receptor expression in oral squamous cell carcinoma , 2012, BMC Cancer.

[5]  M. Gassmann,et al.  Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. , 2009, The Journal of endocrinology.

[6]  A. Sytkowski,et al.  The erythropoietin receptor in normal and cancer tissues. , 2008, Critical reviews in oncology/hematology.

[7]  M. Velasco,et al.  Tumor vaccines in renal cell carcinoma , 2008, World Journal of Urology.

[8]  H. Kanayama,et al.  Phase I trial of personalized peptide vaccination for cytokine‐refractory metastatic renal cell carcinoma patients , 2007, Cancer science.

[9]  M. Allaf,et al.  Erythropoietin receptor expression in the human urogenital tract: immunolocalization in the prostate, neurovascular bundle and penis , 2007, BJU international.

[10]  Y. Kodera,et al.  The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206 , 2007, Bone Marrow Transplantation.

[11]  J. Patard,et al.  Renal cell carcinoma guideline. , 2007, European urology.

[12]  T. Shuin,et al.  WT1 (Wilms' Tumor 1) Peptide Immunotherapy for Renal Cell Carcinoma , 2007, Microbiology and immunology.

[13]  H. Shiku,et al.  Generation of peptide-specific CD8+ T cells by phytohemagglutinin-stimulated antigen-mRNA-transduced CD4+ T cells. , 2006, Journal of immunological methods.

[14]  Zheng Zhang,et al.  Coexpression of erythropoietin and erythropoietin receptor in sporadic clear cell renal cell carcinoma , 2006, Cancer biology & therapy.

[15]  Motoyoshi Tanaka,et al.  A Phase I Trial of Vaccination of CA9-Derived Peptides for HLA-A24-Positive Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[16]  G. Parmiani,et al.  A listing of human tumor antigens recognized by T cells: March 2004 update , 2005, Cancer Immunology, Immunotherapy.

[17]  A. Vortmeyer,et al.  Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  A. Vortmeyer,et al.  Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. , 2003, Cancer research.

[19]  S. Saga,et al.  Induction of antigen specific cellular immunity by vaccination with peptides from MN/CA IX in renal cell carcinoma. , 2003, Oncology reports.

[20]  Satoru Takahashi,et al.  Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. , 2002, Blood.

[21]  Adrian L. Harris,et al.  Association of hypoxia‐inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma , 2002 .

[22]  W. Kaelin,et al.  Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.

[23]  H. Takasu,et al.  A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation , 2002, Cancer Immunology, Immunotherapy.

[24]  P. Ratcliffe,et al.  Oxygen sensors and angiogenesis. , 2002, Seminars in cell & developmental biology.

[25]  S. Joseph,et al.  Erythropoietin (Epo) and EpoR expression and 2 waves of erythropoiesis. , 2001, Blood.

[26]  C. Westenfelder,et al.  Erythropoietin stimulates proliferation of human renal carcinoma cells. , 2000, Kidney international.

[27]  A. Goldberg,et al.  Proteolysis and class I major histocompatibility complex antigen presentation , 1999, Immunological reviews.

[28]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[29]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[30]  W. Vainchenker,et al.  Autocrine stimulation by erythropoietin and autonomous growth of human erythroid leukemic cells in vitro. , 1991, The Journal of clinical investigation.

[31]  D. Khayat,et al.  An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. , 2008, European journal of cancer.

[32]  H. Rammensee,et al.  Peptides naturally presented by MHC class I molecules. , 1993, Annual review of immunology.